Global G-Protein Coupled Receptors (GPCR) Market Outlook, 2031

G-protein coupled receptors are the largest family of membrane receptors in the human body, with roughly 800 members that sense hormones, neurotransmitters, peptides, lipids, light, odours and tastes and transmit signals into cells through G proteins and arrestins. Because they control so many physiological processes, they are among the most important drug targets, and around one-third of approved medicines act on a GPCR. The GPCR market covers therapeutics that target these receptors, such as GLP-1 and GIP receptor agonists for diabetes and obesity, muscarinic, dopamine and serotonin receptor drugs for psychiatric and neurological disorders, opioid, cannabinoid and calcitonin gene-related peptide receptor drugs for pain and migraine, beta-adrenergic and angiotensin receptor drugs for cardiovascular and respiratory disease, and chemokine receptor drugs in immunology and oncology. It also includes research tools such as GPCR assays, cell lines, membrane preparations, stabilised receptors, antibodies and screening services. Participants include Novo Nordisk, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Pfizer, Structure Therapeutics, Septerna, Nxera Pharma, Thermo Fisher Scientific, Revvity, Eurofins DiscoverX and Promega. Target biology and drug design determine competitiveness.

Demand is driven above all by the rapid growth of incretin-based medicines that act on GLP-1 and related receptors for obesity, diabetes and their complications, together with new mechanisms in neuroscience and continued GPCR drug discovery enabled by structural biology and AI. Between 2024 and 2026, regulators approved a first-in-class muscarinic receptor treatment for schizophrenia in September 2024, the first new mechanism for the condition in decades; expanded incretin medicines into obstructive sleep apnoea in December 2024 and metabolic dysfunction-associated steatohepatitis in August 2025; approved the first oral GLP-1 pill for weight management in December 2025; and approved an oral small-molecule GLP-1 receptor agonist in April 2026. These approvals widened patient populations and shifted competition toward oral formulations, better tolerability and lower cost. Manufacturing capacity, pricing pressure, insurance coverage, supply shortages and patent expiries shaped the market. Through 2031, key variables are obesity drug coverage, oral and next-generation incretins, generic competition, neuroscience launches, structure-based discovery and biased agonist design. Companies with strong manufacturing and differentiated mechanisms are expected to hold an advantage.

Drivers •Explosive Growth of Incretin Medicines for Obesity and Metabolic Disease: GLP-1, GIP and related receptor agonists have become some of the largest-selling medicines, with indications expanding from diabetes and obesity to cardiovascular risk reduction, sleep apnoea, liver disease and kidney disease. Oral versions, including small-molecule agonists that do not need injection or food restrictions, broaden access. Many companies are developing next-generation multi-receptor agonists. Demand far exceeds earlier forecasts. Demand is strong.

•New Mechanisms in Neuroscience, Pain and Immunology: Novel GPCR drugs are reaching patients in areas with high unmet need, including muscarinic receptor treatments for schizophrenia, calcitonin gene-related peptide receptor drugs for migraine, orexin receptor drugs for insomnia and chemokine and lipid receptor drugs in immunology. Advances in structural biology reveal binding sites and receptor states, enabling more selective drugs. Biased agonists aim to improve safety. Pipelines are broad. Growth is solid.

Challenges •Pricing, Access and Manufacturing Constraints: High prices for incretin medicines strain insurance budgets, and coverage for obesity treatment remains limited in many health systems, restricting access. Rapid demand growth has caused supply shortages for injectable products, requiring large investments in manufacturing capacity. Compounded and counterfeit products have appeared. Patent expiries for older GPCR drugs bring generic competition. Price negotiations are intensifying. Margins face pressure.



•Complex Biology, Selectivity and Tolerability: GPCRs are membrane proteins that are difficult to purify and study, and many receptors share similar binding sites, making selective drugs hard to design. Side effects, such as gastrointestinal effects with incretins, cardiovascular effects with some receptor drugs and dependence with opioids, limit use. Many orphan receptors still lack known ligands. Translating receptor biology into clinical benefit is uncertain. Development risk is high.

Trends •Oral Small Molecules and Multi-Receptor Agonists: Companies are developing oral small-molecule GLP-1 receptor agonists that can be manufactured at scale like conventional tablets, as well as oral peptides and injectable agonists that act on several receptors, such as GLP-1, GIP, glucagon and amylin receptors, to increase weight loss and metabolic benefits. Longer-acting injections and maintenance strategies are being studied. Competition is intensifying. Pipelines are crowded. Adoption is rising.

•Structure-Based and AI-Driven GPCR Drug Discovery: Cryo-electron microscopy has made it possible to determine structures of many GPCRs in different activation states, and AI structure prediction and virtual screening are used to find new ligands, allosteric modulators and biased agonists. Companies are targeting previously undrugged receptors, including orphan GPCRs. Stabilised receptor technologies and new assay platforms support screening. Partnerships with large pharmaceutical companies are increasing. Interest is growing.

Metabolic and endocrine disorders lead because incretin medicines dominate GPCR sales, while neuroscience and immunology grow through new first-in-class mechanisms. Metabolic and endocrine disorders are the largest therapeutic area segment because GLP-1 and dual GLP-1 and GIP receptor agonists for type 2 diabetes and obesity have become some of the best-selling medicines, and their use is expanding into cardiovascular risk reduction, obstructive sleep apnoea, steatohepatitis and chronic kidney disease. Oral formulations and small-molecule agonists are widening access. Central nervous system disorders form a large segment, including antipsychotics acting on dopamine and serotonin receptors, new muscarinic receptor drugs for schizophrenia, migraine treatments acting on calcitonin gene-related peptide receptors, orexin receptor antagonists for insomnia and opioid receptor drugs for pain. Cardiovascular and respiratory diseases rely on long-established GPCR drugs such as beta-blockers, angiotensin receptor blockers and beta-agonists, many now generic, so this segment grows slowly. Oncology and immunology use GPCR-targeted drugs in areas such as chemokine receptors and lipid receptors and are growing with new targets. Other areas include gastrointestinal, urology and ophthalmology. Each therapeutic area has distinct competitive dynamics, pricing pressures and patent timelines. Through the forecast period, metabolic disorders are expected to remain the largest and fastest growing segment by value, while neuroscience grows strongly as first-in-class mechanisms reach more patients and as additional psychiatric and neurological indications are approved.


Agonists lead because incretin and other receptor-activating medicines drive sales, while allosteric modulators and biased ligands grow as discovery tools improve. Agonists, which activate receptors, are the largest drug type segment because GLP-1, GIP and other peptide hormone receptor agonists account for a very large share of GPCR medicine sales, and agonists are also used for pain, respiratory disease, migraine and other conditions. Next-generation agonists target several receptors at once to increase efficacy. Antagonists, which block receptor activity, form a large and established segment, including many antipsychotics, antihistamines, angiotensin receptor blockers, beta-blockers and migraine drugs, and many are now available as generics. Allosteric modulators, which bind outside the main ligand site to fine-tune receptor activity, are a growing segment because they can offer greater selectivity and fewer side effects. Biased ligands, which activate selected signalling pathways, are being developed to keep therapeutic effects while reducing adverse effects. Several biased ligands have reached clinical trials, although results so far have been mixed. Antibodies targeting GPCRs are an emerging segment, as engineering and stabilised receptor technologies make these difficult targets more accessible to biologic drugs. Through the forecast period, agonists are expected to remain the largest segment, while allosteric modulators, biased ligands and antibodies grow fastest as structure-based design and new screening technologies improve the ability to target receptors selectively across therapeutic areas.


Small molecules lead in number of approved drugs, while peptides and biologics lead growth by value through incretin medicines. Small molecules account for the largest number of approved GPCR drugs because most classic receptor medicines, including antipsychotics, antihistamines, beta-blockers, angiotensin receptor blockers and opioids, are small molecules that can be taken orally, manufactured cheaply and penetrate tissues, including the brain. Oral small-molecule GLP-1 receptor agonists are a major new development, as they could combine incretin benefits with easier manufacturing and administration. Peptides are the fastest growing segment by value because GLP-1 and multi-receptor agonists are peptide-based medicines given by injection or as oral tablets with absorption enhancers, and they generate very large revenues. Peptide engineering improves half-life and receptor selectivity. Biologics, including monoclonal antibodies that target GPCRs or their ligands, form a growing segment in migraine, immunology and oncology. Other modalities, such as RNA-based and gene therapy approaches, are at early stages. Manufacturing considerations differ sharply between modalities, affecting cost, scale and supply security. Peptide synthesis capacity, in particular, has expanded rapidly to meet incretin demand. Through the forecast period, peptides are expected to remain the largest segment by value, small molecules regain growth through oral incretins and new neuroscience drugs, and biologics expand as antibody engineering makes more receptors accessible to treatment with targeted therapies across many diseases.


Hospital and retail pharmacies lead distribution, while online pharmacies grow fastest as obesity medicines and direct-to-consumer models expand. Retail pharmacies are the largest distribution channel because most GPCR medicines, including diabetes and obesity treatments, antipsychotics, antihistamines, cardiovascular drugs and migraine medicines, are prescribed for long-term outpatient use and dispensed through community pharmacies. Pharmacists also play a role in managing supply shortages and counselling on injection techniques. Hospital pharmacies are an important channel for treatments started in hospital, injectable drugs used in acute care and specialist neurology and psychiatry medicines. Online pharmacies are the fastest growing channel because obesity medicines are increasingly prescribed through telehealth services and direct-to-consumer programmes run by manufacturers, which offer home delivery and sometimes lower cash prices. Specialty pharmacies handle high-cost biologic medicines. Manufacturer programmes selling directly to patients at fixed cash prices are increasingly important for obesity medicines. Insurance coverage rules strongly influence which channel patients use. Research tools for GPCR discovery, including assays, cell lines and screening services, are sold directly to pharmaceutical companies, contract research organisations and academic laboratories. Through the forecast period, retail pharmacies are expected to remain the largest channel, while online pharmacies and direct-to-consumer models grow fastest as demand for obesity treatment continues to expand and as more patients pay directly for medicines not fully covered by insurance plans.


North America is the leading region, driven by very high demand for GLP-1 and dual incretin medicines for diabetes and obesity and early launches of new GPCR mechanisms. Regulators approved Cobenfy, a muscarinic receptor treatment for schizophrenia, in September 2024; Zepbound for obstructive sleep apnoea in December 2024; Wegovy for steatohepatitis in August 2025; the Wegovy pill as the first oral GLP-1 for weight management in December 2025; and Foundayo, the oral GLP-1 orforglipron, in April 2026. Supply shortages, compounded products, insurance coverage and price negotiations shaped the market. Direct-to-consumer and telehealth channels expanded. By 2031, growth is expected from oral incretins, new indications and neuroscience drugs.


Europe is a major region and home to leading GPCR drug makers, including Novo Nordisk in Denmark, along with AstraZeneca and research-focused companies such as Nxera Pharma. Demand for incretin medicines is high, but reimbursement for obesity treatment varies by country and is often limited. Regulators have approved incretin medicines for obesity and cardiovascular risk reduction. Strong academic research in structural biology supports GPCR discovery. Manufacturing investments are expanding capacity. By 2031, growth is expected from wider obesity coverage, oral formulations and new mechanisms.


Asia-Pacific is the fastest growing region. China has a large diabetes population and a fast-growing biotechnology sector developing GLP-1 and multi-receptor agonists, including many licensed to global companies. Japan approved incretin medicines for obesity and has strong GPCR research, and South Korea and India are expanding use of incretin drugs. Generic semaglutide is expected in some markets as patents expire. By 2031, the region is expected to show the highest growth.


April 2026: FDA approves Foundayo (orforglipron) for weight management: Eli Lilly's once-daily oral GLP-1 receptor agonist was approved without food or water restrictions, adding a small-molecule oral option to incretin therapy.

December 2025: FDA approves Wegovy pill for weight management: Oral semaglutide became the first GLP-1 pill approved for chronic weight management, expanding treatment options beyond injections.

August 2025: FDA approves Wegovy for metabolic dysfunction-associated steatohepatitis: Semaglutide gained approval for adults with steatohepatitis and moderate to advanced liver fibrosis, extending GLP-1 receptor agonists into liver disease.

December 2024: FDA approves Zepbound for obstructive sleep apnoea: Tirzepatide, a dual GIP and GLP-1 receptor agonist, became the first medicine approved for moderate to severe obstructive sleep apnoea in adults with obesity.

September 2024: FDA approves Cobenfy for schizophrenia: The combination of xanomeline and trospium, acting on muscarinic receptors, became the first new mechanism approved for schizophrenia in decades.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global G-Protein Coupled Receptors (GPCR) Market with its segments and regional outlook
• Various drivers and challenges
• Ongoing trends and developments
• Key developments and regulatory milestones

By Therapeutic Area
• Metabolic and endocrine disorders
• Central nervous system disorders
• Cardiovascular and respiratory diseases
• Oncology and immunology
• Other therapeutic areas

By Drug Type
• Agonists
• Antagonists
• Allosteric modulators
• Biased ligands
• Antibodies

By Molecule Type
• Small molecules
• Peptides
• Biologics
• Other modalities

By Distribution Channel
• Retail pharmacies
• Hospital pharmacies
• Online pharmacies
• Specialty pharmacies